253 related articles for article (PubMed ID: 17346612)
1. A generalized concept of power helped to choose optimal endpoints in clinical trials.
Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
[TBL] [Abstract][Full Text] [Related]
2. An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint.
Borm GF; Houben RM; Welsing PM; Zielhuis GA
J Clin Epidemiol; 2006 Jan; 59(1):1-6. PubMed ID: 16360554
[TBL] [Abstract][Full Text] [Related]
3. Sample size and the probability of a successful trial.
Chuang-Stein C
Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
[TBL] [Abstract][Full Text] [Related]
4. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
5. A simple method for calculating power based on a prior trial.
Borm GF; Bloem BR; Munneke M; Teerenstra S
J Clin Epidemiol; 2010 Sep; 63(9):992-7. PubMed ID: 20573484
[TBL] [Abstract][Full Text] [Related]
6. Optimal design of clinical trials comparing several treatments with a control.
Marschner IC
Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312
[TBL] [Abstract][Full Text] [Related]
7. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
8. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the statistical power for multiple tests: a case study.
Yeo A; Qu Y
Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
[TBL] [Abstract][Full Text] [Related]
10. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
11. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
12. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
Lai TL; Shih MC; Zhu G
Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
[TBL] [Abstract][Full Text] [Related]
13. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
Leon AC
J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
[TBL] [Abstract][Full Text] [Related]
14. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
15. Mid-course sample size modification in clinical trials based on the observed treatment effect.
Jennison C; Turnbull BW
Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
[TBL] [Abstract][Full Text] [Related]
16. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
Cook RJ; Wei W
Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
[TBL] [Abstract][Full Text] [Related]
17. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
18. The use of a registry database in clinical trial design: assessing the influence of entry criteria on statistical power and number of eligible patients.
Peelen L; Peek N; de Jonge E; Scheffer GJ; de Keizer NF
Int J Med Inform; 2007; 76(2-3):176-83. PubMed ID: 16829179
[TBL] [Abstract][Full Text] [Related]
19. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
20. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
